logo
Bank of Canada to hold rates at 2.75% but cut at least twice more this year: Reuters poll

Bank of Canada to hold rates at 2.75% but cut at least twice more this year: Reuters poll

Yahoo4 days ago

By Mumal Rathore and Indradip Ghosh
BENGALURU (Reuters) - The Bank of Canada will hold interest rates at 2.75% on Wednesday as policymakers await further news on an economy that grew faster than expected last quarter, with at least two more cuts likely this year, according to a majority of economists in a Reuters poll.
That strong consensus around the upcoming decision came after data on Friday showed the economy grew quicker than predicted last quarter, at 2.2%.
The surprising growth was primarily driven by exports as U.S. companies rushed to stockpile Canadian goods before U.S. President Donald Trump's tariffs kick in.
Lower household spending and weak domestic demand, however, suggest a downturn is coming. Also, Trump's recent announcement he would double tariffs on imported steel and aluminum to 50% could further worsen the outlook.
Still, solid economic growth in Q1 and core inflation flirting with the upper end of the BoC's 1-3% target range will provide ample reason for the central bank to hold rates this week for a second straight meeting.
Over 75% of economists, 20 of 26, polled by Reuters said so following the gross domestic product data release. That is in line with interest rate futures pricing.
"There isn't urgency from the growth numbers, and there is caution from the core inflation numbers," said Douglas Porter, chief economist at BMO Capital Markets, who expects the BoC to hold.
"The overall GDP numbers have been surprisingly resilient. While the economy is certainly not as strong as the headline suggests, the reality is (that) it has managed to grind out some modest growth."
Prior to the release, economists were unsure about the decision. Among top Canadian banks, BMO, CIBC and TD shifted their call to a pause from a cut while Scotiabank stood pat on their earlier view of no change.
The BoC has already cut the rate by a cumulative 225 basis points since June 2024.
Although there was no clear consensus on where rates would be by end-2025, nearly 75% of economists - 17 of 23 - said the BoC would cut rates at least twice more this year, including eight forecasting another two reductions, seven saying a further three cuts and two a further four.
"While we would argue a cut would be the right step, odds are the BoC won't deliver one just yet, having signaled that it's less willing to be forward-looking amidst considerable uncertainty over the outlook," said Avery Shenfeld, chief economist at CIBC.
"So we look for a pause (on Wednesday), but one accompanied by a message that leaves the door open for rate relief ahead."
Last month, BoC Governor Tiff Macklem explicitly warned of a possible growth slowdown in coming quarters. But the BoC will refresh its economic outlook in July, which could be another reason to wait this week.
The economy grew 0.1% in April, better than feared, but that is unlikely to be sustained. It will contract 1.0% and 0.5% this quarter and next, respectively, poll medians showed. If realised, that would meet the technical definition of a recession.
"Whatever happens next, the BoC cannot assume the status quo will hold ... We believe Canadian growth is likely to slow sharply through the middle part of the year, justifying further rate cuts," said Andrew Kelvin, head of Canadian and global rates strategy at TD Securities.
(Other stories from the Reuters global economic poll)

Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Kovo+ Announces Management Change
Kovo+ Announces Management Change

Yahoo

time13 minutes ago

  • Yahoo

Kovo+ Announces Management Change

Calgary, Alberta--(Newsfile Corp. - June 6, 2025) - Kovo+ Holdings Inc. (TSXV: KOVO) ("Kovo" or the "Company") announces that Mark Detz has resigned as Chief Financial Officer of the Company, and Kovo accepted his resignation effective as of June 4, 2024. "As a core member of senior management, Mark has been an important member of our team, and we thank him for his contributions to the Company," said Justin Anderson, Chief Executive Officer of Kovo. Following a confidential recruitment process, the Company has identified and selected a candidate to succeed Mr. Detz as Chief Financial Offer and expects to announce the appointment in due course. About Kovo+ Holdings Inc. Kovo is a versatile technology company leading the charge in AI initiatives to drive impact and innovation across diverse industries. Kovo remains committed to its core business-model of strategic growth opportunities within mid-market Medical Billing firms, where exploitative business optimization synergies exist. Moving forward, Kovo will integrate accretive broader healthcare sector additions to its portfolio and opportunities beyond in multiple new markets. Dedicated to revolutionizing business process optimization through technological advancements and evolving AI-applied methods, Kovo embodies a commitment to ensured and enduring profitability. To learn more about Kovo and to keep up to date on Kovo news, visit Cautionary Note Regarding Forward-Looking Information Statements contained in this news release that are not historical facts are "forward-looking information" or "forward-looking statements" within the meaning of applicable Canadian securities laws. Such forward-looking statements or information are provided to inform the Company's shareholders and potential investors about management's current expectations and plans relating to the future and include, but are not limited to, (i) expectations regarding the Chief Financial Officer appointment; and (ii) expectations regarding the timing and appointment thereof. Readers are cautioned that reliance on such information may not be appropriate for other purposes. Any such forward-looking information may be identified by words such as "anticipate", "proposed", "estimates", "would", "expects", "intends", "plans", "may", "will", and similar expressions. Forward-looking statements or information are based on a number of factors and assumptions that have been used to develop such statements and information, but which may prove to be incorrect. By its nature, such forward-looking information is subject to various risks and uncertainties, which could cause the actual results and expectations to differ materially from the anticipated results or expectations expressed. Although the Company believes that the expectations reflected in such forward-looking statements or information are reasonable, undue reliance should not be placed on forward-looking statements because the Company can give no assurance that such expectations will prove to be correct. The forward-looking information in this news release reflects the current expectations, assumptions and/or beliefs of the Company based on information currently available to the Company. Any forward-looking information speaks only as of the date on which it is made and, except as may be required by applicable securities laws, the Company disclaims any intent or obligation to update any forward-looking information, whether as a result of new information, future events or results or expressly qualified by this cautionary statement. Contact Information For further information, please contact: investors@ Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release. To view the source version of this press release, please visit Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data

Tesla's Optimus humanoid robot program head exiting firm, Bloomberg News reports
Tesla's Optimus humanoid robot program head exiting firm, Bloomberg News reports

Yahoo

time28 minutes ago

  • Yahoo

Tesla's Optimus humanoid robot program head exiting firm, Bloomberg News reports

(Reuters) -The head of Tesla's Optimus program, Milan Kovac, is leaving the company, casting uncertainty over chief executive Elon Musk's humanoid robot project, Bloomberg News reported on Friday, citing a person familiar with the matter. Kovac, vice president and head of engineering for Optimus, told colleagues on Friday that he was departing, effective immediately. Ashok Elluswamy, who leads Tesla's autopilot teams, will take on Kovac's role, the report said. Tesla, Kovac and Elluswamy did not immediately respond to Reuters requests for comment. Musk has earlier said he expected Tesla to make thousands of Optimus robots this year. He said in April that China's export restrictions on rare-earth magnets had affected production of the humanoid robots. Tesla has shifted focus to launching the robots and its robotaxi service, with much of the company's valuation hanging on that bet. "The only things that matter in the long term are autonomy and Optimus," Musk told CNBC in an interview in May.

Pharmaris Canada to Lead Sales and Marketing for Vimy Pharma Products Across Canada
Pharmaris Canada to Lead Sales and Marketing for Vimy Pharma Products Across Canada

Yahoo

time31 minutes ago

  • Yahoo

Pharmaris Canada to Lead Sales and Marketing for Vimy Pharma Products Across Canada

TORONTO, ON / / June 6, 2025 / Two proudly Canadian pharmaceutical companies announced today a strategic partnership that reinforces their shared commitment to serving Canadian patients. Under the agreement, Pharmaris will assume responsibility for all sales and marketing activities for Vimy Pharma product portfolio across Canada. This landmark collaboration unites two homegrown Canadian pharmaceutical organizations, both with deep roots in the Canadian healthcare landscape. The partnership exemplifies Canadian innovation and entrepreneurship in action, while strengthening domestic pharmaceutical capabilities and expertise. Built by Canadians for Canadians, both companies have demonstrated their dedication to advancing healthcare solutions that address the unique needs of the Canadian market. This alliance further cements their shared vision of making healthcare more accessible and affordable for patients from coast to coast. "Our partnership with Vimy Pharma marks a big step forward advancing access to critical medicines for Canadians,"said Michael Sine, President of Pharmaris. "This alliance demonstrates our shared commitment to putting Canadian patients first." "We are pleased to partner with Pharmaris in broadening access to essential medicines," stated Farris Smith, President of Vimy Pharma,"as we strive to improve outcomes and make a meaningful difference to patients." ABOUT PHARMARIS CANADA Pharmaris Canada is a pharmaceutical company committed to delivering high-quality healthcare products that support the well-being of Canadians. Pharmaris Canada is part of a large diversified global group based out of Vancouver, B.C started by two pharmacists. The group has business interests spanning pharmaceuticals, residential and commercial real estate, property development, hospitality, mobility solutions, and retail pharmacy operations. Pharmaris Canada offers a distinctive portfolio of over-the-counter (OTC) and generic pharmaceutical products. Our OTC range includes a Canadian-made line of iron supplements and a broad selection of German-manufactured effervescent vitamin tablets. As one of the few companies to successfully integrate branded OTC and generic medicines, Pharmaris has developed strong capabilities in brand management, prescription navigation, and market expansion. With a presence in 16 countries and a team of 585 employees, most of whom have been with the organization for over five years, Pharmaris continues to grow its global footprint through innovation and operational excellence. ABOUT VIMY PHARMA Vimy Pharma is a Canadian pharmaceutical company committed to ensuring a stable, reliable supply of essential medicines, reducing dependence on foreign sources, and supporting good-paying jobs for Canadians in life sciences and advanced manufacturing. Our products are made to the highest standards of quality and safety, meeting rigorous Health Canada guidelines. At Vimy Pharma, our team is inspired by the groundbreaking achievements of Drs. Frederick Banting and Charles Best, and James B. Collip whose discovery in Canada of insulin revolutionized treatments and changed millions of lives worldwide. Their spirit of ingenuity, collaboration, and commitment to public health continues to guide our approach as we develop and manufacture high-quality, affordable, essential medicines for Canadian health challenges. MEDIA CONTACTMichael SinePresident, Pharmaris Canadamichael@ Farris SmithFounder & President, Vimy Pharmaceuticals - 30 - SOURCE: Pharmaris View the original press release on ACCESS Newswire Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into the world of global news and events? Download our app today from your preferred app store and start exploring.
app-storeplay-store